ICICI Direct has given Hold recommendation for Lupin with a target price of Rs. 1015 in its research report issued on Dec 14, 2021

ICICI Direct’s research report on Lupin

Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.


We maintain HOLD as key addressable issues such as progress on the margins front, pricing pressure and competition in key US products besides pending resolution at other key plants still continue to weigh. We value Lupin at Rs 1015 i.e. 27.5xP/E FY23E EPS.

Leave a Reply

Your email address will not be published. Required fields are marked *